OnKure Therapeutics Inc (OKUR): Prakiraan konsensus analis

OnKure Therapeutics Inc (OKUR) is developing high-precision tumor therapies, aiming for patent leadership and the establishment of premium pricing for its developments. This price trend chart, with a current reading of 15.44, reflects the asset's dynamics. The business relies on R&D processes that are independent of market cycles and operates within a stable US legal framework, remaining fully insulated from international political conflicts.

Bagan rega target: OnKure Therapeutics, Inc. (OKUR) kanggo 08.10.2024 - 22.10.2026

Rincian analitis perusahaan OnKure Therapeutics Inc (OKUR)

Indikator analitis utama onkuretherapeutics.com (OKUR):

Rega bursa onkuretherapeutics.com|OKUR - Bagan rega target|Kapitalisasi pasar OnKure

Analisis fundamental perusahaan:OnKure Therapeutics, Inc. (OKUR)

Produk asli OnKure Therapeutics Inc

To minimize capital risks, investors compare the current asset value with its fair potential. In the case of OnKure Therapeutics Inc (OKUR), success depends on the commercialization of PI3Kalpha inhibitors; therefore, the market consensus forecast reflects the gap between the market price and the average expectations of oncotherapy experts, where an upward curve signals a revaluation of the business's fundamental value relative to industry standards.

Perusahaan pesaing

ONC - Rata-rata rega prakiraan|Bagan rega target Halozyme HALO|Prakiraan konsensus analis Revolution Medicines Inc RVMD|AAPG: Target konsensus|CGON - Prakiraan konsensus analis|UroGen Pharma Ltd. (URGN) - Bagan rega target|bicara.com - Konsensus nilai wajar|PSNL (Personalis) - Prakiraan konsensus analis|Target konsensus Erasca Inc (ERAS)|Prakiraan konsensus analis DCTH|Prakiraan konsensus analis Y-mAbs Corp (YMAB)|Bagan rega target Aura Biosciences, Inc. AURA|CADL: Prakiraan gabungan firma investasi|Accuray - Prakiraan konsensus analis|SELLAS Life Sciences (SLS) - Target konsensus|ACTU: Prakiraan konsensus analis|Rata-rata rega prakiraan Citius Oncology Inc (CTOR)|Bagan rega target TuHURA Biosciences Inc.|TARA: Konsensus nilai wajar|Target konsensus FATE (Fate Therapeutics)|WHWK (aadibio.com) - Konsensus nilai wajar|Prakiraan konsensus analis TCRX (TScan Therapeutics, Inc.)|CSBR - Target konsensus|XBIT: Target konsensus|CVM - Prakiraan konsensus analis|OS Therapies (OSTX) - Bagan rega target|Radiopharm Theranostics Ltd - Konsensus nilai wajar|ARTV (Artiva Biotherapeutics Inc.) - Prakiraan konsensus analis|Rata-rata rega prakiraan Adlai Nortye Limited ANL|Bagan rega target Veru Inc. (VERU)|TPST - Rata-rata rega prakiraan|Bagan rega target Xilio Therapeutics XLO|RENB: Prakiraan gabungan firma investasi|MURA - Bagan rega target|KAPA - Prakiraan konsensus analis|GDTC (w2.cytomed.sg) - Target konsensus|Curis (CRIS) - Prakiraan konsensus analis|Bagan rega target Apollomics Inc.|THAR: Konsensus nilai wajar|Prakiraan konsensus analis ADVB|GNPX - Rata-rata rega prakiraan|Calidi Biotherapeutics, Inc. - Target konsensus|Konsensus nilai wajar SBFM|XBIO: Target konsensus|Salarius Pharmaceuticals Inc - Rega prakiraan analis|PPBT: Prakiraan konsensus analis|American Oncology Network, Inc. - Konsensus nilai wajar|BGNE (BeiGene, Ltd.) - Prakiraan konsensus analis|Rata-rata rega prakiraan checkpointtx.com CKPT|Bagan rega target Elevation Oncology, Inc. (ELEV)|ICAD (icadmed.com) - Konsensus nilai wajar|Prakiraan konsensus analis IKNA (Ikena Oncology)|Prakiraan konsensus analis Notable Labs Corp NTBL|VIRX - Bagan rega target|Bagan tingkat prakiraan MOR|NAYA: Prakiraan konsensus analis|Rata-rata rega prakiraan Ascentage Pharma Group International (AAPGV)